Data gathered: November 27
AI Stock Analysis - Conduit Pharmaceuticals (CDT)
Analysis generated November 21, 2024. Powered by Chat GPT.
Conduit Pharmaceuticals is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic solutions. The company focuses on treatments for chronic diseases and rare conditions, tapping into niche markets with significant unmet medical needs. Conduit's pipeline includes various stages of clinical development, which positions the company as potentially high-risk but with substantial upside opportunities should their treatments gain approval.
Stock Alerts - Conduit Pharmaceuticals (CDT)
 |
Conduit Pharmaceuticals | November 27 Price is up by 9.5% in the last 24h. |
|
Conduit Pharmaceuticals | November 26 Price is up by 5.5% in the last 24h. |
|
Conduit Pharmaceuticals | November 25 Price is down by -7% in the last 24h. |
|
Conduit Pharmaceuticals | November 22 Price is down by -8.6% in the last 24h. |
Alternative Data for Conduit Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | 18 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 56 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,088 | Sign up | Sign up | Sign up |
| Twitter Mentions | 169 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 4 | Sign up | Sign up | Sign up |
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
| Price | $0.10 |
| Target Price | Sign up |
| Volume | 14,040,000 |
| Market Cap | $9.4M |
| Year Range | $0.09 - $3.67 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune DisordersNovember 21 - GlobeNewswire |
|
 |
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of DirectorsNovember 19 - Yahoo |
Conduit Pharmaceuticals announces new addition to autoimmune pipelineNovember 4 - Yahoo |
|
|
Conduit Pharmaceuticals Announces New Addition to its Autoimmune PipelineNovember 3 - Yahoo |
Conduit Pharmaceuticals Announces Debt Restructuring and Additional NotesNovember 1 - GlobeNewswire |
|
Conduit Pharmaceuticals announces debt restructuring and additional notesOctober 31 - Seeking Alpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 50,000 | 2.7M | -2.7M | -6.5M | -6.1M | -0.074 |
| Q2 '24 | 604M | 3.1M | -3.1M | -5.4M | -5.3M | -0.073 |
| Q1 '24 | 536M | 2.8M | -2.8M | -3.6M | -3M | -0.048 |
| Q4 '23 | 0 | 810,000 | -1.1M | 280,000 | 1.9M | -0.015 |
| Q3 '23 | 150,000 | 1.1M | -920,000 | 2.6M | 2M | -0.003 |
Insider Transactions View All
| Nirland Ltd filed to sell 6,092,000 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 7,031,009 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 8,400,000 shares at $0.1. October 7 '24 |
| Nirland Ltd filed to sell 9,900,000 shares at $0.1. October 2 '24 |
| Nirland Ltd filed to sell 10,233,177 shares at $0.1. October 2 '24 |
Similar companies
Read more about Conduit Pharmaceuticals (CDT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Conduit Pharmaceuticals?
The Market Cap of Conduit Pharmaceuticals is $9.4M.
What is the current stock price of Conduit Pharmaceuticals?
Currently, the price of one share of Conduit Pharmaceuticals stock is $0.10.
How can I analyze the CDT stock price chart for investment decisions?
The CDT stock price chart above provides a comprehensive visual representation of Conduit Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Conduit Pharmaceuticals shares. Our platform offers an up-to-date CDT stock price chart, along with technical data analysis and alternative data insights.
Does CDT offer dividends to its shareholders?
As of our latest update, Conduit Pharmaceuticals (CDT) does not offer dividends to its shareholders. Investors interested in Conduit Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Conduit Pharmaceuticals?
Some of the similar stocks of Conduit Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.